With the signing of the deal, shares of Orchid Pharma surged 10% in trade to hit an intraday high of Rs 1,047, nearing the 52-week high mark of Rs 1,094 apiece on the NSE. The triple-digit PE pharma stock traded above the Rs 1,000-mark with the surge in the intraday share price, defying the Nifty 50 benchmark index.
According to media reports, the regulator has communicated through the Indian Drug Manufacturers' Association (IDMA) to identify companies that can immediately supply ifosfamide injection, a generic chemotherapy drug used in the treatment of several cancers, including testicular, bladder and lung cancer.
Cipla share price opened at Rs 1,372 against a previous close of Rs 1,351.80 and extended gains by over 4% to hit an intraday high of Rs 1,409 apiece so far on the NSE.
Zaynich, approved for complicated urinary tract infections and pyelonephritis, is aimed at treating infections caused by drug-resistant bacteria — an area where doctors globally are facing shrinking treatment options as antimicrobial resistance rises.
Developers had pushed back hard, citing fears of a domestic solar cell shortage, higher procurement costs and execution delays.
The stellar numbers for Gland Pharma were largely driven by a combination of factors, including strong US traction led by new launches.
Vohra's track record at Cipla makes him a strategic fit for Cohance, which is itself navigating a similar transition, from volume manufacturing toward value-based partnerships with innovator and specialty pharma clients.
Currently, IEX acts as India's leading platform for spot electricity price discovery.
China's move to curb exports of sulphuric acid—particularly the by-product from copper and zinc smelting—signals a shift toward domestic prioritisation ahead of its peak crop planting season.
Acutaas shares have soared 85% over the last six months. The company is finding massive market success by pivoting to electric vehicle battery solvents.
Among the standout performers, State Bank of India led the charts with its highest-ever quarterly profit, buoyed by a sharp rise in non-interest income.
These heavy underperformers between January and November posted notable gains in December.
With most big names failing to impress, the year turned into a classic stock-picker’s game, proof that even in a dull market, the right pills can still cure portfolios.
Lower US sales of gRevlimid are a major drag for Dr. Reddy’s, Zydus, Aurobindo, and Cipla.
The pharmaceutical sector has seen a flurry of new deals, partnerships, and drug launches this week, presenting potential significant growth opportunities in oncology, biosimilars, and diabetes care.
As US drug makers reduce dependence on Chinese players, Indian CDMOs are poised to capture new opportunities.
Brokerages see the near-term outlook as “benign” but diverge on the policy path, weighing factors like GST cuts, monsoon effects, and imported inflation shocks.
Tata Power's revenue rose 4% to Rs 18,035 crore in the quarter ended June.
Sun Pharma's Q1 net profit fell 19% year-on-year to Rs 2,154 crore in the June quarter.
Margin narrows to 24.2% versus 28% in the year-ago period.
